NGVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ingevity Corp (NGVT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is weak, with declining revenue, net income, and EPS. Additionally, technical indicators do not show a clear bullish trend, and there are no significant positive trading signals or catalysts to justify immediate action. It is better to hold off on buying until there are clearer signs of recovery or growth.
The MACD histogram is negative and expanding (-0.835), indicating bearish momentum. RSI is neutral at 38.984, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 67.002) but below the pivot point (71.605). Overall, the technical indicators suggest a lack of strong upward momentum.
The company achieved its highest free cash flow in five years ($274 million) and reduced net leverage to 2.6x. Additionally, management plans to sell non-core businesses and focus on core growth areas, which could improve financial stability and shareholder returns in the long term.
The resignation of the finance chief may impact investor confidence and financial strategy. Q4 financials showed significant declines in revenue (-14.63% YoY), net income (-644.58% YoY), and EPS (-650.00% YoY). The company also reported a GAAP EPS of -$2.37, indicating profitability challenges. Additionally, the stock lacks strong trading trends or significant insider/hedge fund activity.
In Q4 2025, revenue dropped by 14.63% YoY to $255.1 million, net income fell by 644.58% YoY to -$90.4 million, and EPS declined by 650% YoY to -2.53. Gross margin increased slightly to 34.42% (+0.94% YoY), but overall financial performance remains weak.
Analysts are mixed on the stock. Wells Fargo raised the price target to $65 but remains neutral due to uncertainty around business alternatives. BMO Capital raised the price target to $70 and maintains an Outperform rating, citing potential benefits from portfolio optimization and debt reduction. However, the overall sentiment remains cautious.
